Rigel Pharmaceuticals announced $58.8 million in total revenues and $8.7 million net income for Q1 2026, driven by a 26% increase in net product sales. The company is progressing its Phase 1b study of R289, targeting lower-risk myelodysplastic syndrome, with dose expansion enrollment expected to complete in H2 2026. Rigel reaffirmed its 2026 revenue guidance of $275-$290 million and anticipates positive net income for the full year while continuing clinical development and business growth.
Annaly Capital Management is rated Buy at $22.94 per share, with a fair value estimate of $25.55, implying an 11.4% price upside. The company's diversified portfolio across Agency MBS, Residential Credit, and MSR supports a strong blended target retu...
Evernorth, the largest XRP digital asset treasury, is moving closer to becoming a publicly traded company via a merger with Armada Acquisition Corp. II, a SPAC. The U.S. SEC has approved their Form S-4 registration, allowing them to proceed with shar...
Ripple has recommended withdrawing the pending XChainBridge (XLS-38) amendment for the XRP Ledger after deciding that its primary use case—connecting the XRPL mainnet with an EVM-compatible sidechain—is already fulfilled by Axelar. The amendment woul...
Clearfield cut its FY2026 guidance because of delays in broadband projects linked to slow government BEAD program rollout and fiber supply constraints. However, the company secured a $22 million order for hyperscale data centers, validating its growt...
Charles Schwab is expanding its Schwab Crypto platform by adding Solana, Avalanche, and Chainlink to its existing Bitcoin and Ethereum offerings. This move aims to provide investors with more options to build diverse digital asset portfolios while le...
